Interestingly, trastuzumab deruxtecan shows clinical benefits in “HER2-mutant” non-small cell lung cancer, regardless of the HER2 expression/amplification status [66,67]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.